Thrombin Activity Propagates in Space During Blood Coagulation as an Excitation Wave

N. M. Dashkevich,†‡ M. V. Ovanesov,§ A. N. Balandina,†§ S. S. Karamzin,‡ P. I. Shestakov,†‡ N. P. Soshitova,† A. A. Tokarev,‡ M. A. Panteleev,†‡ and F. I. Ataullakhanov†‡†∗

†Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia; ‡HemaCore (Hematological Corporation), Moscow, Russia; †Center for Biologics Evaluation and Research, U. S. Food and Drug Administration, Bethesda, Maryland; §Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia; and ‡Physics Department, Moscow State University, Moscow, Russia

ABSTRACT Injury-induced bleeding is stopped by a hemostatic plug formation that is controlled by a complex nonlinear and spatially heterogeneous biochemical network of proteolytic enzymes called blood coagulation. We studied spatial dynamics of thrombin, the central enzyme of this network, by developing a fluorogenic substrate-based method for time- and space-resolved imaging of thrombin enzymatic activity. Clotting stimulation by immobilized tissue factor induced localized thrombin activity impulse that propagated in space and possessed all characteristic traits of a traveling excitation wave: constant spatial velocity, constant amplitude, and insensitivity to the initial stimulation once it exceeded activation threshold. The parameters of this traveling wave were controlled by the availability of phospholipids or platelets, and the wave did not form in plasmas from hemophilia A or C patients who lack factors VIII and XI, which are mediators of the two principal positive feedbacks of coagulation. Stimulation of the negative feedback of the protein C pathway with thrombomodulin produced nonstationary patterns of wave formation followed by deceleration and annihilation. This indicates that blood function can as an excitable medium that conducts traveling waves of coagulation.

INTRODUCTION

Blood coagulation is a space- and time-dependent process of plasma jellification that leads to formation of a plug preventing blood loss upon vascular injury. It is an intricate network of serine proteases, cofactors, and inhibitors, which are arranged into a proteolytic cascade with at least six positive and negative feedback loops. The presence of nonlinear positive feedbacks in this spatially heterogeneous reaction-diffusion system led to a prediction (1,2) that it can function as an excitable medium—a spatially distributed, dissipative, nonlinear system, in which complex spatiotemporal phenomena such as traveling waves or Turing structures can be observed. Excitable media play prominent roles in chemistry, physics, engineering, and human sciences; two classic examples in biology include neural impulse propagation (3) and morphogenesis (4).

Although the importance of positive and negative feedback loops in the spatial propagation of coagulation has been confirmed by experiments and theoretical analyses (5–7), the hypothetical traveling wave of thrombin has not been directly observed. Fibrinogen, the primary substrate for thrombin, is quickly depleted before the maximal thrombin concentration is reached. Indeed, plasma becomes fully clotted when only 5% of the total thrombin is generated. Although the clot density may be slightly predictive of thrombin activity in a 200-μm zone near thrombogenic cell monolayers (8), it has not been possible to reconstruct the spatiotemporal thrombin distribution inside the growing clot, nor to predict the shape of possible traveling thrombin waves.

In this study, we designed a fluorogenic substrate-based four-dimensional-biochemistry approach to measure distribution of thrombin as a function of space and time. Using this strategy, we demonstrated formation of excitation waves in blood plasma and identified the responsible mechanism.

MATERIALS AND METHODS

Materials

Reagents were obtained from the following sources: 7-amino-4-methylcoumarin (Sigma-Aldrich, St. Louis, MO); Z-Gly-Gly-Arg-AMC (Bachem, Torrance, CA); rabbit thromboplastin, factor VIII assay (Renam, Moscow, Russia); brain phosphatidylserine and egg phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL); low melting point agarose (Fluka Chemie AG, Buchs, Switzerland); corn trypsin inhibitor (Gamma, Pushchino, Russia); factor VIII (Hemophil M, Baxter Russia, Moscow, Russia); factor XI and rabbit lung thrombomodulin (Haematologic Technologies, Essex Junction, VT); Actichrome TF test (American Diagnostica, Stamford, CT); factor VIII-deficient plasma (George King Biomedical, Overland Park, KS); and factor XI-deficient plasma (HRF, Raleigh, NC). The glycoprotein Ib-IXa antagonist Monastram was a generous gift of Prof. A. V. Mazurov (Russian Cardiology Research and Production Center, Moscow, Russia).

Experimental setup

Experiments were performed with a specially designed videomicroscopy system (Fig. 1A) that allows for the simultaneous observation of spatial fibrin clot propagation and thrombin generation. The plasma sample was placed in the experimental chamber, and clotting was activated by bringing

Submitted June 6, 2012, and accepted for publication October 1, 2012.

*Correspondence: ataullakhanov.fazly@gmail.com

Editor: Leslie Loew.

© 2012 by the Biophysical Society

0006-3495/12/11/2233/8 $2.00

http://dx.doi.org/10.1016/j.bpj.2012.10.011
an activator with a tissue factor (TF)-coated surface in contact with plasma. The chamber was maintained at 37°C and illuminated with red (625 nm) or ultraviolet (UV) (365 nm) LEDs (Optotech, Hsinchu, Taiwan). Clot growth was detected with red light scattering, and AMC fluorescence was excited with UV LEDs. Fluorescence and scattered red light passing through the macro lens were detected by a charge-coupled device system (Apogee Imaging Systems, Roseville, CA). Images under red and blue light were acquired once per minute. Data analysis is described in detail in the Supporting Material.

Blood collection and plasma preparation

Before the procedure, all volunteers provided written informed consent. Experiments were performed with approval from the Ethical Committees of the National Research Center for Hematology and Center for Theoretical Problems of Physicochemical Pharmacology. Normal plasma pools (3–7 plasma samples) were obtained from freshly drawn human blood from healthy volunteers. Blood was collected into 3.8% sodium citrate with corn trypsin inhibitor (final concentration 0.2 mg/ml) to minimize contact activation. Platelet-rich plasma was obtained by centrifugation for 8 min at 100 × g. The platelet count was adjusted to 250,000 platelets/μL, and the pH level was stabilized at 7.4 by the addition of 20 mM Hepes. To prevent clot retraction, the glyco- protein IIb/IIIa-inhibiting antibody fragment Monafra (25 μg/mL) was used, and experiments were performed in 0.5% low melting point agarose. Samples were prepared as described previously. After recalcification, plasma was prewarmed to 42°C for 2 min. Agarose solution was added, and the mixture was incubated in the experimental cuvette for 3 min to form a gel. The experiment was started as described previously.

Spatial clot growth experiments in platelet-rich plasma

Blood was collected directly into citrate with corn trypsin inhibitor (final concentration 0.2 mg/ml) to minimize contact activation. Platelet-rich plasma was obtained by centrifugation for 8 min at 100 × g. The platelet count was adjusted to 250,000 platelets/μL, and the pH level was stabilized at 7.4 by the addition of 20 mM Hepes. To prevent clot retraction, the glycoprotein IIb/IIIa-inhibiting antibody fragment Monafra (25 μg/mL) was used, and experiments were performed in 0.5% low melting point agarose. Samples were prepared as described previously. After recalcification, plasma was prewarmed to 42°C for 2 min. Agarose solution was added, and the mixture was incubated in the experimental cuvette for 3 min to form a gel. The experiment was started as described previously.

Spatial clot growth experiments in defibrinated plasma

Platelet-free plasma (prepared as described previously) was defibrinated by incubation with 0.02 NIH thrombin units of ancistron (Tekhnologiya-Standart, Barnaul, Russia) at 37°C for 1 h, followed by fibrin clot removal. The experiments were performed in an agarose gel, as described previously.

RESULTS

Method description

To study spatial dynamics of blood coagulation, we developed a fluorogenic substrate-based videomicroscopy method for time- and space-resolved imaging of thrombin activity (Fig. 1 A). Clotting was initiated by a layer of immobilized TF, a transmembrane glycoprotein that activates coagulation on the damaged vascular wall surface. Clotting propagated from the activation surface into the bulk of plasma. The
fluorogenic thrombin-specific peptide substrate Z-Gly-Gly-Arg-AMC was added to the plasma, so that its cleavage by thrombin produced a fluorescent molecule of AMC (Fig. 1 B). The growing fibrin clot was sequentially illuminated by red or UV light to image light scattered by the fibrin clot or spatiotemporal distribution of AMC fluorescence, respectively (Fig. 1 C). Fibrin concentration profiles were obtained from the light scattering intensity (see Fig. 1 E), and the AMC distribution (Fig. 1 D) was used to calculate thrombin (Fig. 1 F). The central idea for our approach is derived from the standard mass-balance equation for AMC, which infers that if the rate laws of fluorophore production and diffusion are known the experimentally measured AMC distribution can then be used to reconstruct the source term in this equation, i.e., thrombin activity as a function of space and time. The basic reaction-diffusion equation

\[
\frac{\partial [AMC]}{\partial t} = D_{AMC} \cdot \frac{\partial^2 [AMC]}{\partial x^2} + \frac{k_{cat} \cdot [S] \cdot [Ii]}{K_M + [S]}, \quad (1)
\]

was transformed

\[
[Ii] = \frac{K_M + [S]}{k_{cat} \cdot [S]} \cdot \left( \frac{\partial [AMC]}{\partial t} - D_{AMC} \cdot \frac{\partial^2 [AMC]}{\partial x^2} \right). \quad (2)
\]

Thus, the time- and space-resolved thrombin activity distribution was calculated by numerically solving an inverse reaction-diffusion problem (10) (see the Supporting Material for the detailed algorithm description) modified to account for AMC binding in plasma and fluorescence distortion caused by the fibrin clot (Fig. S1 and Fig. S2 in the Supporting Material).

**Thrombin propagation determines formation of fibrin clot**

Fibrin clot initiated by a TF-covered surface steadily propagated in normal plasma at a constant spatial velocity of ~20–50 μm/min (Fig. 1 E) and was apparently driven by an impulse-like wave of thrombin with a constant thrombin peak amplitude of 50–100 nM (Fig. 1 F and Movie S1). To investigate if clot formation regulates thrombin generation via reversible inhibition of thrombin by fibrin, or via protection of thrombin from inhibition by antithrombin III, or via acceleration of factor XI activation, we depleted fibrinogen using a fibrin-cleaving protease from snake venom. In defibrinated plasma, thrombin spatial propagation was qualitatively similar (Fig. S3), indicating that thrombin wave propagation is an independent phenomenon not determined by formation of polymerized fibrin clot.

**Thrombin wave reveals properties of a traveling wave in an excitable medium**

An important aspect of traveling waves in active media is the formation of identical waves after a relatively broad range of stimuli because the traveling wave is regulated by properties of active media and not by the history of its activation. To investigate the effect of initial stimulus on the properties of propagating thrombin wave, we prepared activators of different potency by changing the density of immobilized TF. The waves obtained by using 90 pmol/m² (Fig. 2 A) or 4 pmol/m² (Fig. 2 B) of TF were very similar (Fig. 2, C and D). It should be noted that the lowest TF density corresponds to just a few TF molecules per squared micron; this is, however, only by an order of magnitude lower than TF density on highly active fibroblasts (6), and comparable to macrophages and endothelial cells (11). Thus, thrombin activity waves travel continuously at a constant spatial velocity, have a constant shape and nondecaying amplitude, and are independent of the initial conditions once the activation signal exceeds the threshold: these are necessary and sufficient traits of a traveling wave in an excitable medium (12).

In contrast, this wave was sensitive to the properties of the medium. It did not propagate steadily in platelet-free plasma that was not supplemented with phospholipids (Fig. 2 E; Fig. S4) or platelets (Fig. 2 F), able to accelerate membrane-dependent reactions comprising the positive feedback loops of blood coagulation. Thrombin peak amplitude was particularly sensitive to phospholipid concentration, whereas the spatial propagation velocity of this wave was not.

**Positive feedback loops are essential for wave propagation**

Excitation wave formation requires the existence of positive feedback loops that support self-sustained propagation independently of the activator. Blood coagulation possesses at least one such feedback: factor XI activation with thrombin (13) as shown in Fig. 3 A. Other positive feedbacks, such as factor V, VII, and VIII activation, do not lead to formation of independently active enzymes and are therefore incapable of sustaining indefinite propagation in space. Severe factor XI deficiency, or hemophilia type C, is a rare bleeding disease. The mechanism of this bleeding is controversial, because of the apparently complementary role of factor XI in the coagulation cascade: it is unclear why humans require the minute quantities of factor IXa produced by thrombin-activated factor Xla, if there is an abundance of factor IXa produced by VIIa-TF (6). One possible explanation in view of the findings of this study could be that factor XI activation by thrombin forms an excitation wave that propagates clotting far from the activation site than could be necessary for large wound sealing.

To test this hypothesis experimentally, we performed studies with factor XI-deficient plasma from a hemophilia C patient (Fig. 3 B). A traveling wave did not form in this plasma, but was generated when a normal concentration of factor XI was added. Factor VIII deficiency, a severe
bleeding disorder known as hemophilia type A, also prevented thrombin wave formation (Fig. S5). Interestingly, computer simulation analysis suggested that factor XI deficiency is in a way more fundamental for the traveling wave phenomenon far from the activator, because factor XIa is an enzyme that is indispensable for autocatalytic thrombin production far from the activator, whereas factor VIIIa is only a cofactor (Figs. S6–S8). Although this might seem paradoxical, as factor VIII is well known to be much more important clinically, however this actually agrees with the previous observation that factor VIII is important for clot formation at smaller distances (1–2 mm) from the activator, whereas factor XI becomes essential and indispensable at later stages for larger clots (6), i.e., exactly when the traveling wave is observed.

**Protein C pathway is responsible for thrombin wave limitation in space**

Our previous studies suggested that different modules in the coagulation network are responsible for specific tasks such as activation threshold formation, spatial propagation, and termination of this propagation (14). In particular, stimulation of the anticoagulant protein C pathway with naturally occurring allosteric regulator of thrombin thrombomodulin (Fig. 3 A) was previously found to regulate clot size (6). To study the possible effect of this pathway on the traveling wave of thrombin, we performed experiments with different thrombomodulin concentrations. Stimulation of the anticoagulant protein C pathway led to nonstationary patterns of wave formation followed by its deceleration and annihilation (Fig. 4, A and B, and Movie S2). Computer simulation is shown in Fig. S9. Clot propagation was initiated normally and then abruptly stopped at different distances from the activator. Several interesting and unusual patterns of traveling wave propagation were observed: at low thrombomodulin concentration, the initial velocity was steady, followed by deceleration and thrombin peak decrease, whereas at higher concentrations, thrombin peak ran for some distance, and then decelerated and stopped. Existence of various modes of wave propagation and pattern formation is another known feature of active media.

Normally TM is localized at the undamaged vessel walls. To compare effects of soluble and immobilized TM we performed additional computer simulation (Fig. S10) showing that TM immobilized far from a TF-coated surface can stop thrombin propagation as well.
DISCUSSION

In summary, we observed that the contact of plasma with TF results in TF-dependent thrombin generation in a 0.5- to 1-mm area near the TF-expressing surface. Within 10–40 min, a thrombin wave was formed that moved away from the area of activation at a rate and height that were independent of the initial activating signal. Our main finding is that blood can function as an excitable medium to support thrombin wave propagation. This phenomenon is easy to observe and reproduce mathematically and experimentally, and may serve as an example and research tool for synergetics research.

How are the observed time and space scales related to the (patho)physiological ones? The traveling wave of our study requires ~1–1.5 mm to form, and it has a wavefront width of 0.2–0.3 mm. Such a wave can be imagined in a large wound (Fig. 4C), where it can efficiently spread fibrin formation. This is in line with the usual clinical presentation of hemophilia C in large-scale wounds or surgery (15). In case of hemophilia C, absence of the travelling wave of thrombin, that can form a large-scale fibrin clot, could lead to severe bleeding. Therefore, the patients do not have problems with small wounds as it does not require rapid long-distance thrombin propagation. Thrombomodulin present in abundance in the normal endothelium would prevent this wave from entering healthy vessels. Thus, the fact that blood can function as an excitable medium to support thrombin wave propagation not only provides a new, to our knowledge, biological nonlinear dynamic system, but also appears to be important for fulfillment of the physiological function of the coagulation system.

We proposed a possible mode for the thrombin traveling wave in vivo, which should help provide a novel, to our knowledge, understanding of the role of thrombin-induced factor XI activation in blood clotting (Fig. 4C). On the basis of our experiments, computer simulations, and the clinical presentation of hemophilia C (i.e., uncontrollable bleeding, usually in cases of large-scale wounds or surgery (15)), we
speculate that the excitation wave of thrombin, formed as a result of the positive feedback loop of factor XI activation, propagates the clotting process across large wounds and far from the TF-expressing surface, resulting in efficient wound sealing. However, when thrombomodulin is abundant (e.g., in normal endothelium), the wave is prevented from entering healthy vessels.

Factor XI activation with thrombin reportedly can produce additional thrombin to protect the fibrin clot from fibrinolysis (16) and to provide sustained thrombin generation (17). However, to achieve these effects, it would be evolutionarily simpler to induce more rapid thrombin activation, instead of introducing a new positive feedback loop. Rapid and steady spatial signal propagation across significant distances in a heterogeneous system cannot be resolved in a way other than through creation of an excitable medium with traveling waves, as evidenced by neural impulse propagation. In this study, we experimentally confirm this role of factor XI, which we previously proposed on the basis of computer simulation results (1,2).

Although steady propagation of a traveling wave can be beneficial, it also can be a potentially dangerous dynamic factor. Factor XI plays a significant role in thrombosis (18), which is caused by intravascular formation of platelet-fibrin clots that obstruct blood flow through blood vessels. Thrombosis is a ubiquitous complication and cause of numerous diseases and conditions, such as atherosclerosis, trauma, stroke, infarction, cancer, and sepsis. Up to 70% of sudden cardiac deaths are due to thrombosis (19), and sudden cardiac deaths kill ~400,000 people annually in the United States alone (20). Thrombin-dependent factor XI activation feedback may also explain why factor XI is a potential target of antithrombotic drugs (21).

FIGURE 4 Traveling wave propagation is stopped by thrombomodulin: possible implications for confining a hemostatic plug to the wound. (A) Spatiotemporally resolved distribution of thrombin in normal plasma supplemented with different concentrations of thrombomodulin, as indicated in the panels. Plasma is supplemented with 10 μM phospholipids. Activation is with 4 pmol TF/m². A typical experiment (out of n = 5) is shown. (B) Clot size (main plot), spatial velocity (left inset), and thrombin peak amplitude (right inset) as functions of time for different thrombomodulin concentrations. (C) Hypothetical function of the traveling wave of thrombin in vivo. In a sufficiently large wound, it is necessary to turn all of the blood into a gel, and to spread the clot from the TF-containing injury site into the bulk of the blood. This task is possible, because thrombin propagation can be self-sustained due to factor XI feedback activation, which explains the bleeding upon large injuries in hemophilia C. Abundant thrombomodulin in the healthy blood vessel endothelium prevents the traveling wave from entering the healthy vasculature.

SUPPORTING MATERIAL

Data analysis, computer simulations, supporting data, references (22)–(77), and two movies are available at http://www.biophysj.org/biophysj/supplemental/S0006-3495(12)01114-9.

The authors thank Prof. A. V. Mazurov for his generous gift of Monafram. We are indebted to Dr. V. I. Sarbash for his contribution to the construction of the experimental setup, and to Dr. O. A. Fadeeva who prepared and characterized activators. We thank Mr. James Kurasawa and Dr. Andrey Sarafanov, Centers for Biologics Evaluation and Research, Food and Drug Administration (CBER, FDA) for providing us with anti-FVIII antibody, Naveen Jha (CBER, FDA) for his help in additional experiment performing, and John W. Weisel and Rustem I. Litvinov (University of Pennsylvania) for critical reading of the manuscript and valuable suggestions.

The study was supported by the Russian Foundation for Basic Research grants 10-01-91055, 11-04-00303, 11-04-12080, 12-04-00652, 12-04-00438, 12-04-32095, 12-04-33055 and by the Russian Academy of Sciences...
REFERENCES


23. Reference deleted in proof.


26. Reference deleted in proof.

27. Reference deleted in proof.


